Your browser doesn't support javascript.
loading
Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.
Saunders, Kevin O; Verkoczy, Laurent K; Jiang, Chuancang; Zhang, Jinsong; Parks, Robert; Chen, Haiyan; Housman, Max; Bouton-Verville, Hilary; Shen, Xiaoying; Trama, Ashley M; Scearce, Richard; Sutherland, Laura; Santra, Sampa; Newman, Amanda; Eaton, Amanda; Xu, Kai; Georgiev, Ivelin S; Joyce, M Gordon; Tomaras, Georgia D; Bonsignori, Mattia; Reed, Steven G; Salazar, Andres; Mascola, John R; Moody, M Anthony; Cain, Derek W; Centlivre, Mireille; Zurawski, Sandra; Zurawski, Gerard; Erickson, Harold P; Kwong, Peter D; Alam, S Munir; Levy, Yves; Montefiori, David C; Haynes, Barton F.
Afiliação
  • Saunders KO; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: kevin.saunders@duke.edu.
  • Verkoczy LK; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Pathology, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: laurent.verkoczy@duke.edu.
  • Jiang C; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Zhang J; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Parks R; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Chen H; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Housman M; Department of Cell Biology, Duke University, Duke University Medical Center, Durham, NC 27710, USA.
  • Bouton-Verville H; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Shen X; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Trama AM; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Scearce R; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Sutherland L; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Santra S; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Newman A; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Eaton A; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA.
  • Xu K; Vaccine Research Center, National Institute of Allergy and Infectious Disease, Bethesda, MD 20814, USA.
  • Georgiev IS; Vaccine Research Center, National Institute of Allergy and Infectious Disease, Bethesda, MD 20814, USA.
  • Joyce MG; Vaccine Research Center, National Institute of Allergy and Infectious Disease, Bethesda, MD 20814, USA.
  • Tomaras GD; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA.
  • Bonsignori M; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Reed SG; Infectious Disease Research Institute, Seattle, WA 98102, USA.
  • Salazar A; Oncovir, Inc., Washington, DC 20008, USA.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Disease, Bethesda, MD 20814, USA.
  • Moody MA; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Pediatrics, Duke School of Medicine, Durham, NC 27710, USA.
  • Cain DW; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Centlivre M; Vaccine Research Institute (VRI), Inserm U955, Université Paris Est, AP-HP, Hôpital H. Mondor - A. Chenevier, Créteil, 94000, France.
  • Zurawski S; Baylor Institute for Immunology Research, Dallas, TX 75204, USA; Vaccine Research Institute (VRI), Inserm U955, Université Paris Est, AP-HP, Hôpital H. Mondor - A. Chenevier, Créteil, 94000, France.
  • Zurawski G; Baylor Institute for Immunology Research, Dallas, TX 75204, USA; Vaccine Research Institute (VRI), Inserm U955, Université Paris Est, AP-HP, Hôpital H. Mondor - A. Chenevier, Créteil, 94000, France.
  • Erickson HP; Department of Cell Biology, Duke University, Duke University Medical Center, Durham, NC 27710, USA.
  • Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Disease, Bethesda, MD 20814, USA.
  • Alam SM; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Biomedical Engineering, Duke Pratt School of Engineering, Durham, NC 27710, USA.
  • Levy Y; Vaccine Research Institute (VRI), Inserm U955, Université Paris Est, AP-HP, Hôpital H. Mondor - A. Chenevier, Créteil, 94000, France.
  • Montefiori DC; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA.
  • Haynes BF; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine and Immunology, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: barton.haynes@dm.duke.edu.
Cell Rep ; 21(13): 3681-3690, 2017 12 26.
Article em En | MEDLINE | ID: mdl-29281818
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Anticorpos Neutralizantes Limite: Animals Idioma: En Revista: Cell Rep Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Anticorpos Neutralizantes Limite: Animals Idioma: En Revista: Cell Rep Ano de publicação: 2017 Tipo de documento: Article